Detalles de la búsqueda
1.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Cytotherapy
; 24(7): 742-749, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35219582
2.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264412
3.
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours.
Br J Clin Pharmacol
; 87(3): 1291-1302, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32736411
4.
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Invest New Drugs
; 38(3): 800-811, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31297636
5.
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Lancet Oncol
; 19(1): 51-64, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29217288
6.
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Invest New Drugs
; 35(5): 627-633, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283779
7.
Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
AJR Am J Roentgenol
; 209(4): 722-732, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28705059
8.
Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344.
J Pharmacol Exp Ther
; 358(2): 199-208, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27255112
9.
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
Invest New Drugs
; 32(3): 510-7, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24395457
10.
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
Invest New Drugs
; 32(3): 518-25, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24458261
11.
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.
BMC Cancer
; 12: 16, 2012 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-22244160
12.
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.
Am J Clin Oncol
; 45(8): 352-365, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35848749
13.
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Clin Pharmacokinet
; 48(3): 199-209, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19385713
14.
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
Clin Breast Cancer
; 9(1): 16-22, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19299235
15.
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
Liver Int
; 29(2): 284-90, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18482274
16.
Automatic trial eligibility surveillance based on unstructured clinical data.
Int J Med Inform
; 129: 13-19, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31445247
17.
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
PLoS One
; 14(11): e0224420, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31751384
18.
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Cancer Chemother Pharmacol
; 61(3): 515-24, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17505827
19.
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Cancer Chemother Pharmacol
; 62(1): 97-109, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17805538
20.
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Clin Cancer Res
; 13(4): 1238-45, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317835